EA031627B1 - Модуляторы аденозиновых рецепторов a - Google Patents

Модуляторы аденозиновых рецепторов a Download PDF

Info

Publication number
EA031627B1
EA031627B1 EA201791657A EA201791657A EA031627B1 EA 031627 B1 EA031627 B1 EA 031627B1 EA 201791657 A EA201791657 A EA 201791657A EA 201791657 A EA201791657 A EA 201791657A EA 031627 B1 EA031627 B1 EA 031627B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cyano
ylcarbamoyl
thiazol
carboxylic acid
group
Prior art date
Application number
EA201791657A
Other languages
English (en)
Russian (ru)
Other versions
EA201791657A1 (ru
Inventor
Хулио Кастро-Паломино Лария
Хуан Камачо Гомес
Original Assignee
Палобиофарма С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Палобиофарма С.Л. filed Critical Палобиофарма С.Л.
Publication of EA201791657A1 publication Critical patent/EA201791657A1/ru
Publication of EA031627B1 publication Critical patent/EA031627B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA201791657A 2015-01-22 2016-01-22 Модуляторы аденозиновых рецепторов a EA031627B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201530085A ES2578363B1 (es) 2015-01-22 2015-01-22 Moduladores de los receptores A3 de adenosina
PCT/ES2016/070032 WO2016116652A1 (es) 2015-01-22 2016-01-22 Moduladores de los receptores a3 de adenosina

Publications (2)

Publication Number Publication Date
EA201791657A1 EA201791657A1 (ru) 2017-12-29
EA031627B1 true EA031627B1 (ru) 2019-01-31

Family

ID=55359537

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791657A EA031627B1 (ru) 2015-01-22 2016-01-22 Модуляторы аденозиновых рецепторов a

Country Status (22)

Country Link
US (1) US10238637B2 (es)
EP (1) EP3248964B1 (es)
JP (1) JP6637983B2 (es)
KR (1) KR102424575B1 (es)
CN (1) CN107207445B (es)
AU (1) AU2016210091B2 (es)
BR (1) BR112017015597B1 (es)
CA (1) CA2974596C (es)
CY (1) CY1122172T1 (es)
DK (1) DK3248964T3 (es)
EA (1) EA031627B1 (es)
ES (2) ES2578363B1 (es)
HR (1) HRP20191779T1 (es)
HU (1) HUE046307T2 (es)
LT (1) LT3248964T (es)
ME (1) ME03570B (es)
MX (1) MX2017009514A (es)
PL (1) PL3248964T3 (es)
PT (1) PT3248964T (es)
RS (1) RS59388B1 (es)
SI (1) SI3248964T1 (es)
WO (1) WO2016116652A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2676535B1 (es) * 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
KR102155406B1 (ko) 2017-08-18 2020-09-11 주식회사 엘지화학 아연철산화물 내 잔류 Cl의 정량분석 방법
US11458974B2 (en) * 2019-07-08 2022-10-04 Toyota Motor Engineering & Manufacturing North America, Inc. Fleet-based average lane change and driver-specific behavior modelling for autonomous vehicle lane change operation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124000A2 (en) * 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE257703T1 (de) * 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
US6303619B1 (en) 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
AU4506399A (en) 1998-06-05 1999-12-30 Novartis Ag Aryl pyridinyl thiazoles
JP2003522729A (ja) 1998-07-16 2003-07-29 ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア 眼内圧の低下方法
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
PL351148A1 (en) 1999-04-23 2003-03-24 Takeda Chemical Industries Ltd 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
JP2003525291A (ja) 2000-03-01 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ２，４−二置換チアゾリル誘導体
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
AU2002304358B2 (en) 2001-05-31 2007-08-23 Sanofi-Aventis Aminoquinoline and aminopyridine derivatives and their use as adenosine A3 ligands
WO2003008884A1 (en) 2001-07-16 2003-01-30 Maytag Corporation Refrigerator shelves with rolled hook for cantilever fastening
HUP0105406A3 (en) 2001-12-21 2003-12-29 Sanofi Aventis Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
MXPA06001254A (es) 2003-07-31 2006-05-17 Sanofi Aventis Derivados de aminoquinolina y su uso como ligantes de adenosina a3.
EP3002283B1 (en) 2003-12-26 2017-06-14 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
ATE502640T1 (de) 2006-01-26 2011-04-15 Us Gov Health & Human Serv Allosterische a3-adenosin-rezeptormodulatoren
WO2007116106A1 (es) * 2006-04-12 2007-10-18 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina
US20100062994A1 (en) 2006-07-14 2010-03-11 Santaris Pharma A/S Adenosine Receptor Antagonists
AU2007307157A1 (en) 2006-10-06 2008-04-17 The Trustees Of The University Of Pennsylvania Effective delivery of cross-species A3 adenosine-receptor antagonists to reduce intraocular pressure
ES2331220B1 (es) * 2007-10-02 2010-09-23 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
US20090099212A1 (en) 2007-10-16 2009-04-16 Jeff Zablocki A3 adenosine receptor antagonists
US7973051B2 (en) 2007-11-30 2011-07-05 Hoffman-La Roche Inc. Aminothiazoles as FBPase inhibitors for diabetes
WO2010009190A1 (en) 2008-07-16 2010-01-21 King Pharmaceuticals Research And Development, Inc. Methods of treating atherosclerosis
US8796291B2 (en) 2008-08-01 2014-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
US9199102B2 (en) 2009-07-21 2015-12-01 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
WO2012030918A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124000A2 (en) * 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BHATTACHARYA, P. LEONARD, J.T. ROY, K.: "Exploring QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A"3 receptor antagonists using FA and GFA techniques", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 13, no. 4, 15 February 2005 (2005-02-15), GB, pages 1159 - 1165, XP004776019, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2004.11.022 *
BORGHINI, A. PIETRA, D. DOMENICHELLI, P. BIANUCCI, A.M.: "QSAR study on thiazole and thiadiazole analogues as antagonists for the adenosine A"1 and A"3 receptors", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 13, no. 18, 15 September 2005 (2005-09-15), GB, pages 5330 - 5337, XP005021037, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2005.05.041 *
INAMDAR GAJANAN S.; PANDYA AMIT N.; THAKAR HARDIK M.; SUDARSANAM VASUDEVAN; KACHLER SONJA; SABBADIN DAVIDE; MORO STEFANO; KLOTZ KA: "New insight into adenosine receptors selectivity derived from a novel series of [5-substituted-4-phenyl-1,3-thiazol-2-yl] benzamides and furamides", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS., FR, vol. 63, 22 March 2013 (2013-03-22), FR, pages 924 - 934, XP029234025, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2013.03.020 *
MUIJLWIJK-KOEZEN VAN J E, ET AL: "Thiazole and Thiadiazole Analogues as a Novel class of Adenosine Receptor Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, no. 5, 1 March 2001 (2001-03-01), pages 749 - 762, XP002318825, ISSN: 0022-2623, DOI: 10.1021/jm0003945 *

Also Published As

Publication number Publication date
AU2016210091B2 (en) 2019-08-15
EA201791657A1 (ru) 2017-12-29
US20180263963A1 (en) 2018-09-20
SI3248964T1 (sl) 2019-11-29
KR102424575B1 (ko) 2022-07-25
CN107207445B (zh) 2021-03-16
US10238637B2 (en) 2019-03-26
LT3248964T (lt) 2019-10-10
BR112017015597B1 (pt) 2023-02-28
JP2018502881A (ja) 2018-02-01
HUE046307T2 (hu) 2020-02-28
EP3248964B1 (en) 2019-07-17
EP3248964A1 (en) 2017-11-29
JP6637983B2 (ja) 2020-01-29
AU2016210091A1 (en) 2017-08-17
BR112017015597A2 (pt) 2018-03-13
RS59388B1 (sr) 2019-11-29
PT3248964T (pt) 2019-10-28
PL3248964T3 (pl) 2020-02-28
MX2017009514A (es) 2017-11-15
CY1122172T1 (el) 2020-11-25
DK3248964T3 (da) 2019-10-07
ES2578363B1 (es) 2017-01-31
ME03570B (me) 2020-07-20
ES2578363A1 (es) 2016-07-26
CN107207445A (zh) 2017-09-26
HRP20191779T1 (hr) 2019-12-27
ES2750030T3 (es) 2020-03-24
KR20170104612A (ko) 2017-09-15
WO2016116652A1 (es) 2016-07-28
CA2974596A1 (en) 2016-07-28
CA2974596C (en) 2022-11-08

Similar Documents

Publication Publication Date Title
KR102117453B1 (ko) 5-아릴알키닐기에 의해 치환된 벤즈아미드계 화합물 및 이의 제조방법, 약물 조성물과 용도
PT1373191E (pt) Indanilaminas aciladas e sua utilização como fármacos
KR102424575B1 (ko) 아데노신 ａ₃수용체의 조절제
KR102483091B1 (ko) 아데노신 a3 수용체의 조절제
IL293388A (en) History of benzylamide as a transforming growth factor inhibitor in the i/alk5 receptor cell

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM